IMCR News & Events

Reports Q1 revenue $106.68M, consensus $107.08M. "We are proud to report another quarter of strong commercial performance, with KIMMTRAK generating $107 million in net revenues in Q1 2026," said Bahija Jallal, CEO of Immunocore. "The five-year overall survival (OS) data from our Phase 3 trial presented at AACR is a landmark moment. It is the longest OS follow-up ever reported in a randomized trial in metastatic uveal melanoma and underscores the long-term benefit KIMMTRAK delivers to patients. In parallel, we are executing with discipline across our pipeline."

Immunocore announced that Kimmtrak five-year overall survival, OS, was presented in an oral session at the American Association for Cancer Research, AACR, 2026 meeting. This is the longest, prospective Phase 3 randomized trial in patients with unresectable or metastatic uveal melanoma - a disease with a very poor prognosis and a historical survival rate of less than 5% at 5 years. Kimmtrak doubled the likelihood of being alive at five years, with an OS for Kimmtrak of 16% versus 8% in the control arm. These results also represent the longest follow-up reported for any T cell engager in a solid tumor.